Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule

by Business Wire • 2021/07/26 • 0 Comments

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the early completion of patient enrollment of GATHER2, the Company’s 2nd pivotal clinical trial of Zimura® (avacincaptad pegol).

Full Story →

← Riassunto: Santen e IAPB si impegnano a implementare la prima Risoluzione dell’assemblea generale delle Nazioni Unite che riconosce il collegamento tra salute oculare e sviluppo sostenibile

Global Contact Lens Markets Report 2021-2025 – Growing Smart Contact Lens Demand / Increased Consolidation of Market Players / Increasing Shift Towards Daily Lenses / Rising E-Commerce Sales – ResearchAndMarkets.com →

Post navigation